Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCATCo Regulatory News (CAT)

  • This share is currently suspended. It was suspended at a price of 37.50
  • There is currently no data for CAT

EPT Disclosure

16 Jun 2006 11:08

GoldmanSachs International16 June 2006 FORM 38.5(a) DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY (Rule 38.5(a) of the Takeover Code) 1. KEY INFORMATION Name of exempt principal trader Goldman Sachs International Company dealt in CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC Class of relevant security to which the Ordinary Sharesdealings being disclosed relate (Note 1) Date of dealing 15 June 2006 2. DEALINGS (Note 2) (a) Purchases and sales Total number of securities purchased Highest price paid (Note 3) Lowest price paid (Note 3) 0 Total number of securities sold Highest price received (Note 3) Lowest price received (Note 3) 17498 13.1022 GBP 13.101 GBP (b) Derivatives transactions (other than options) Product name, Long/short (Note 4) Number of securities (Note 5) Price per unit (Note 3) e.g. CFDCFD Long 440 13.1022 GBP (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying Product name, Writing, selling, Number of securities to Exercise Type, e.g. Expiry Option money purchasing, which the option relates American,e.g. call varying etc. (Note 5) price European date paid/received peroption etc. unit (Note 3) (ii) Exercising Product name, e.g. call option Number of securities Exercise price per unit (Note 3) 3. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relatingto the voting rights of any relevant securities under any option referred to on this form or relating to the votingrights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form isreferenced. If none, this should be stated. Date of disclosure 16 June 2006 Contact name Peter Highton Telephone number +44-207-774-1935 Name of offeree/offeror with which connected AstrazenecaNature of connection (Note 6) Advisor Notes The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website atwww.thetakeoverpanel.org.uk This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
10th Feb 20212:27 pmRNSHolding(s) in Company
9th Feb 202112:48 pmRNSHolding(s) in Company
5th Feb 20211:08 pmRNSHolding(s) in Company
28th Jan 20217:00 amRNSNet Asset Value(s) & Management Fee Reduction
12th Jan 20217:00 amRNSTransaction in Own Shares - Compulsory Redemption
23rd Dec 20207:00 amRNSTransaction in Own Shares - Compulsory Redemption
15th Dec 20207:00 amRNSNet Asset Value(s)
24th Nov 202012:57 pmRNSAdditional Side Pocket releases
16th Nov 20207:00 amRNSNet Asset Value(s)
2nd Nov 202011:49 amRNSHolding(s) in Company
19th Oct 202010:28 amRNSHolding(s) in Company
16th Oct 20207:00 amRNSNet Asset Value(s)
14th Oct 202010:56 amRNSHolding(s) in Company
12th Oct 20205:10 pmRNSHolding(s) in Company
8th Oct 20207:00 amRNSTransaction in Own Shares-Compulsory Redemption
30th Sep 20207:00 amRNSTransaction in Own Shares - Compulsory Redemption
21st Sep 20207:00 amRNSPortfolio Update - additional Side Pocket releases
21st Sep 20207:00 amRNSNet Asset Value(s)
3rd Sep 20207:00 amRNSTransaction in Own Shares - Compulsory Redemption
27th Aug 20207:00 amRNSPortfolio Update
25th Aug 20207:05 amRNSHalf-year Report
25th Aug 20207:00 amRNSTransaction in Own Shares - Compulsory Redemption
17th Aug 20207:00 amRNSNet Asset Value(s) and Portfolio Update
16th Jul 20202:14 pmRNSHolding(s) in Company
15th Jul 20207:00 amRNSNet Asset Value(s)
13th Jul 20203:47 pmRNSHolding(s) in Company
2nd Jul 202010:22 amRNSTransaction in Own Shares - Compulsory Redemption
24th Jun 20207:00 amRNSTransaction in Own Shares - Compulsory Redemption
11th Jun 20207:00 amRNSNet Asset Value(s) & Portfolio Update
21st May 20202:05 pmRNSResult of AGM
19th May 202011:13 amRNSTransaction in Own Shares - Compulsory Redemption
18th May 20202:43 pmRNSHolding(s) in Company
15th May 20207:00 amRNSNet Asset Value(s)
11th May 20207:00 amRNSTransaction in Own Shares - Compulsory Redemption
27th Apr 20207:00 amRNSNotice of AGM - adaptation of arrangements
21st Apr 20202:27 pmRNSTransaction in Own Shares - Compulsory Redemption
17th Apr 20207:00 amRNSNet Asset Value(s) & Portfolio Update
9th Apr 20207:30 amRNSCompulsory Acqn of Shares
6th Apr 20201:20 pmRNSResult of Special General Meeting & Class Meetings
3rd Apr 202010:27 amRNSAdaptation of shareholder meetings
2nd Apr 20204:41 pmRNSSecond Price Monitoring Extn
2nd Apr 20204:36 pmRNSPrice Monitoring Extension
27th Mar 20207:00 amRNSNet Asset Value(s)
23rd Mar 202012:30 pmRNSAnnual Financial Report
13th Mar 202010:30 amRNSShareholder mtngs & share redemption proposals
11th Mar 20203:56 pmRNSHolding(s) in Company
11th Mar 20207:00 amRNSNet Asset Value(s)
25th Feb 20207:00 amRNSCirc re. Compulsory Redemption of Shares
30th Jan 20207:00 amRNSNet Asset Value and Portfolio Update
7th Jan 20207:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.